Patents Represented by Law Firm Arnall Golden & Gregroy, LLP
  • Patent number: 5811633
    Abstract: The construction of transgenic mouse models for testing potential treatments for Alzheimer's disease are described. The models are characterized by a greater similarity to the conditions existing in naturally occurring Alzheimer's disease, based on expression of all three forms of the .beta.-amyloid precursor protein (APP), APP.sub.695, APP.sub.751, and APP.sub.770), as well as various point mutations based on naturally occurring mutations, such as the London and Indiana familial Alzheimer's disease (FAD) mutations at amino acid 717, and predicted mutations in the APP gene. The APP gene constructs are prepared using the naturally occurring promoter, as well as inducible promoters such as the mouse metallothionine promoter, which can be regulated by addition of heavy metals such as zinc to the mouse's water or diet, and promoters such as the rat neuron specific enolase promoter, human .beta.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 22, 1998
    Inventors: Samuel Wadsworth, Benjamin Snyder, Cha-Mer Wei, Paul J. Leibowitz